Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Playing the QQQQ with Terry and friends. -- Ignore unavailable to you. Want to Upgrade?

To: MJ who wrote (1152)	7/6/2005 4:16:27 PM
From: Walkingshadow	Read Replies (1) \| Respond to of 4814

Hi MJ, Evidently this is the reason STEM is moving on 3 times average volume: 139.142.147.218 StemCells Jumps on Cross-Licensing Deal BOSTON (MarketWatch) - StemCells Inc. jumped notably early Wednesday on news that it had struck a cross-licensing deal with U.K. biotechnology concern ReNeuron. StemCells (STEM: news, chart, profile) shares leapt 6% to $4.75 in mid-morning trade. Under the terms of the deal, StemCells and ReNeuron have cross-licensed their respective neural stem cell technologies for the purpose of developing various stem cell-based therapies. The deal also provides for the companies to pay one another milestone payments and royalties on any successful products derived from the licensed technologies. The agreement also grants StemCells an equity stake in privately held ReNeuron. The companies did not state how large a stake StemCell's will hold in ReNeuron. marketwatch.com ========================= StemCells grants license to ReNeuron, receives stake in UK Stem Cell company (STEM) 4.50 : The co announced today that it has entered into an agreement with ReNeuron, a privately-owned UK biotech corporation. The agreement enables ReNeuron to exploit its "c-mycER" conditionally immortalized adult human neural stem cell technology for therapy and other purposes. In return for the license, STEM received an equity interest in ReNeuron and a cross-license to the exclusive use of ReNeuron's technology for certain diseases and conditions, including lysosomal storage diseases, spinal cord injury, cerebral palsy and multiple sclerosis. ReNeuron will supply cells for STEM's use under the cross-license. The agreement also provides for royalties and milestone payments by each party on the achievement of various goals under the license and cross-license. T